(PEST) domain; for c-MPL, we sequenced the juxtamembrane domain; for PTEN, we restricted our analysis to the C2 domain; for FLT3, we sequenced the juxtamembrane and tyrosine kinase domains; for JAK1, we sequenced the FERM, JH1 and JH2 domains; and for PTPN11, we analyzed exons 3 and 13, which contain the most prevalent mutations identified to date. Genomic DNA and RNA were extracted from patient samples using a Puregene DNA Purification Kit (Qiagen, Valencia, CA, USA) or Trizol (Invitrogen, Carlsbad, CA, USA), respectively. RNA was reverse transcribed using superscript III (Invitrogen) according to the manufacturer's instructions. Primers were designed to amplify the coding regions of interest; sequences are available on request. Mutational analysis carried out by direct sequencing of PCR products generated from reactions with either cDNA or genomic DNA templates.
o55% prolymphocytes (CLL/PL) have different biological features from B-PLL. Although the immunophenotype of B-PLL is different from CLL, one third of B-PLL cases express CD5. 2 Chromosome abnormalities include TP53 gene deletions/mutations, which may explain its aggressive course. 3 The expression of CD38 and ZAP-70 and the mutational status of immunoglobulin heavy chain variable region (IgVH) genes are heterogeneous 4 and, unlike in CLL, they have no prognostic impact; the IgVH gene family usage in B-PLL is different from CLL, CLL/PL or other lymphomas. 4 Nevertheless, the existence of B-PLL as a distinct entity is debated. Therefore, we investigated by microarray analysis, proven useful in the classification of lymphoproliferative disorders, the genomic profile of B-PLL and compared it with CLL to clarify their relationship, to identify differentially expressed transcripts, which may be helpful in diagnostic and therapeutic settings, and to understand B-PLL pathogenesis.
We selected retrospectively cryopreserved blood mononuclear cells containing 495% of malignant cells from 10 de-novo B-PLL and 10 untreated CLL cases. The diagnosis was established by clinical features, lymphocyte morphology and immunophenotype, according to the WHO. 2 In B-PLL, fluorescent in situ hybridization (FISH) for t (11;14) was negative in all but one case (#1449), which was reclassified as leukemic mantle cell lymphoma (MCL); 5 del(17p) was found in 7/10. Three CLL cases showed an increase in prolymphocytes ranging from 11 to 13% (CLL/PL). FISH detected del(17p) in 2/10. Patient's clinical and biologic data are summarized in Supplementary Table S1 and Supplementary Information S1.
Microarray experiments were performed by MRC geneservice (UK HGMP Resource Centre), using the Affymetrix Human U133PLUS2 GeneChip array. The detailed protocol for sample preparation and microarray processing is available online (www.affymetrix.com).
Unsupervised analysis using four different algorithms (average linkage, complete linkage-correlation distance, average linkagecorrelation distance, flexible b-Euclidean distance) and supervised analysis using significance analysis of microarray data (SAM) 6 and prediction analysis for microarray (PAM) 7 were performed. The weighted version of Kolmogorov-Smirnov statistic (WKS) further refined the differentiating transcripts; a functional annotation analysis was applied to the list of selected genes of B-PLL, using the DAVID database (http://david.abcc. ncifcrf.gov) based on Gene Ontology terms and, on the same gene list, a gene set enrichment analysis was performed by the GOEAST software (http://omicslab.genetics.ac.cn/GOEAST/ index.php). Microarray and statistical methods are detailed in Supplementary Information S1.
All four of the unsupervised hierarchical clustering algorithms reproducibly partitioned the samples into two homogeneous distinct groups corresponding to the diagnoses of B-PLL and CLL-CLL/PL ( Figure 1a ) (P-value 0.00001 by Fisher's exact test). Most genes (B77%) differentiating these two diseases, showed 42-fold-change in expression between the groups.
SAM analysis identified 5951 differentially expressed transcripts between CLL and B-PLL: 4916 were over-expressed in B-PLL (fold-change from 25 to 1.3) and 1035 in CLL (foldchange from 43.9 to 1.24). Of them, 3254 differentially expressed transcripts between CLL and B-PLL showed a false discovery rate o1%. Most transcripts (83%) were overexpressed in B-PLL and were involved in cell proliferation/cell cycle (c-MYC, CDK4, RB1, p21, TGFBR3), apoptosis (CASP1), cell metabolism, regulation of transcription (TCF12, SMARCA2, SMARCA4), translation, protein synthesis, signal transduction, adhesion molecules (JAM3, LPXN), immune response and surface antigens (Table 1) . C1757  C1758  C1760  C1544  C1756  C1754  C1755   C1542   C1543  C1759  B1588  B1535  B1314  B1449   B1456   B1513  B1312  B1313  B1515  B1518   1757  1758  1756  1754  1755  1544  1542  1760  1543  1759  1314  1535  1312  1456  1518 Letters to the Editor The over-expression of c-MYC is of interest regarding the pathogenesis of B-PLL. The c-myc oncoprotein promotes cell proliferation and apoptosis, targeting a large number of genes. 8 c-MYC-induced proliferation may be uncoupled from c-MYCinduced apoptosis by a variety of mechanisms: aberrations of BCL2, TP53 or BIM that disable apoptotic programmes; mutations in c-MYC alleles that fail to effectively inhibit the Bcl2 function; AKT over-expression, which can inhibit c-MYCrelated apoptosis.
In B-PLL, the p53 protein activity is often impaired by deletions/mutations of TP53 gene, 3 as seen in seven of our cases. Moreover, the AKT gene resulted up-regulated. Thus, the overexpression of c-MYC and AKT combined with TP53 impairment may have a central role in the pathogenesis of B-PLL, promoting apoptosis inhibition and cell proliferation. Although the molecular lesion involved in c-MYC over-expression is unknown, B-PLL cases showing c-MYC translocations have been reported, [9] [10] [11] [12] [13] [14] including a patient in this study (#1456). 10 Among the genes involved in signal transduction, a large set of transcripts, either with tyrosine kinase (SYK, FYN, BLK, JAK1, JAK3, CSK, HKC) or serine-threonine kinase activity (AKT1, MAP4K1, PRKCB1, PRKACB, STK11), resulted overexpressed in B-PLL, suggesting possible targets for innovative therapies.
Genes over-expressed in CLL belonged to the TGF-b pathway, cell metabolism, regulators of transcription, signal transduction, surface antigens, cytokines receptors and immune response (Supplementary Table S2 ); among them, IL4R, 15 BCL2, cyclin D2, p-selectin.
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The WKS statistics narrowed the initial gene list to 642 probe sets that best partitioned the diagnostic classes (Figure 1b) . Functional annotation analysis of those specific of B-PLL using DAVID software, highlighted a significant enrichment of genes involved in the following categories: mitochondrial activity, oxidoreductase activity, cell proliferation, metabolism, RNA processing, protein synthesis, signal transduction and cytoskeleton (Po0.05). The gene set enrichment analysis by the GOEAST software confirmed the significance of the functional categories identified by DAVID (i.e. mitochondrial activity, oxidoreductase activity, cytoskeleton organization, metabolism, protein biosynthesis). In addition, this analysis selected WNT pathway (P ¼ 0.012), RAS pathway (P ¼ 0.013), JUN kinase activity (P ¼ 0.004) among others represented in B-PLL, as well as genes involved in response to DNA damage (o0.001) (data not shown).
PAM analysis, used as a class-prediction tool, was applied to the samples categorized by a priori defined categories: CLL-CLL/ PL versus B-PLL, CD5 þ versus CD5À and presence or absence of del(17p). Robust class prediction was possible only for the analysis between CLL-CLL/PL versus B-PLL diagnoses. In contrast, the comparison between CD5 þ (n ¼ 13) and CD5À (n ¼ 7) and cases with (n ¼ 9) or without (n ¼ 11) del(17p), showed no reliable class prediction.
PAM analysis identified 46 genes, which most efficiently differentiated the two diseases (Table 2) . Genes distinctively over-expressed in B-PLL in comparison with CLL included: c-MYC; surface antigens CD20 and CD1d; adhesion molecules JAM3 and LPXN; negative regulators of cell cycle, PHB and NME1; genes involved in: proteasome catalytic activity, PSMB9, PSMB10; B-cell maturation and differentiation, EBF, NOTCH2, TPD52; B-cell receptor signal transduction, BANK-1. The most characteristic transcripts of CLL were the costimulatory molecule CTLA4/CD152 and the transcription factor LEF1, claimed to contribute to the apoptotic defect. 18 The existence of B-PLL as a separate entity has been questioned. 11 As we have not included other leukemic lymphomas, we cannot firmly address this topic. However, some genes over-expressed in B-PLL have been described in lymphomas (i.e. the splenic marginal zone lymphoma-related BTK, LPXN, 19 NOTCH2, AKT1 16 or the MCL-related IkBkB,
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CDK4, SMARCA4 16 ), or involved in pathways known to be deregulated in various lymphomas [19] [20] [21] [22] Fi.e. c-myc pathway (C-MYC, MAX, STAT6, IRF2, various hsp), NF-kB (IkBkB, MALT1), Ras/MAP-kinase (MAP4K1, MAP4K4, DUSP22, HRAS), PI3K/AKT (AKT1, PRKACB), proteasome activation pathway (PSMB9, PSMB10) (all with a fold-change from 2 to 14).
B-PLL with t(11;14), documented in up to 20% of cases, have been recently re-classified as splenomegalic leukemic MCL. 5 One of our cases (#1449), originally described as B-PLL and subsequently re-classified as MCL on the basis of t (11;14) , clustered with the other B-PLL in the unsupervised analysis. This is the only case of the series with the simultaneous overexpression of cyclin D1 and c-MYC, a rare finding described in blastoid variant of MCL. 23 Although a single case cannot lead to firm conclusions, we can suggest that the leukemic form of MCL shares with B-PLL a genomic profile mirroring an increased progression through cell cycle.
Our study describes for the first time the gene expression profile of B-PLL, a rare lymphoproliferative disorder. We formally show that B-PLL and CLL-CLL/PL are biologically distinct diseases, each showing a specific and homogeneous genomic signature, and provide new insights on the pathogenesis of B-PLL and on potential molecular targets for novel therapies.
